Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
300485 Beijing Science Sun Pharmaceutical
- 7.55
- +0.26+3.57%
Market Closed Apr 1 15:00 CST
3.64BMarket Cap-52.80P/E (TTM)
7.72High7.31Low105.36KlotVolume7.34Open7.29Pre Close79.97MTurnover3.85%Turnover RatioLossP/E (Static)481.67MShares9.4552wk High1.08P/B2.07BFloat Cap5.7352wk Low8.75Limit Up273.82MShs Float43.34Historical High5.83Limit Down5.62%Amplitude5.73Historical Low0.02Dividend TTM7.59Avg Price43.49KlotAsk0.29%Div YieldTTM100Lot Size59.89KlotBid
Beijing Science Sun Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -12.61%416.48M | -18.01%322.88M | -21.03%214.84M | -17.46%109.54M | -35.12%476.57M | -34.28%393.82M | -29.04%272.04M | -30.92%132.7M | -30.10%734.55M | -25.97%599.23M |
| Operating revenue | -12.61%416.48M | -18.01%322.88M | -21.03%214.84M | -17.46%109.54M | -35.12%476.57M | -34.28%393.82M | -29.04%272.04M | -30.92%132.7M | -30.10%734.55M | -25.97%599.23M |
| Other operating revenue | 136.73%1.53M | ---- | --164.69K | ---- | -20.81%646.39K | ---- | --0 | ---- | -28.80%816.2K | ---- |
| Total operating cost | -24.45%391.08M | -18.60%304.13M | -21.08%205.07M | -20.30%103.93M | -27.15%517.65M | -33.39%373.63M | -27.99%259.86M | -23.50%130.4M | -24.81%710.54M | -21.57%560.94M |
| Operating cost | -0.36%140.43M | -2.20%110.22M | -3.17%74M | -2.40%37.16M | -17.87%140.94M | -18.92%112.7M | -13.95%76.43M | -12.08%38.08M | -5.77%171.61M | -11.83%139M |
| Operating tax surcharges | -5.36%7M | -8.86%4.27M | -9.09%3.64M | -18.86%712K | -16.24%7.4M | -41.61%4.68M | -12.56%4.01M | -73.90%877.46K | -24.74%8.83M | -20.98%8.02M |
| Operating expense | -38.55%141.6M | -30.98%112.6M | -30.64%77.33M | -19.90%43.32M | -37.53%230.43M | -44.56%163.16M | -41.55%111.49M | -42.19%54.08M | -33.56%368.84M | -31.18%294.3M |
| Administration expense | -7.52%57.52M | -2.83%38.39M | -0.51%25.77M | 29.89%13.82M | 1.84%62.2M | -2.14%39.51M | -6.18%25.9M | -21.19%10.64M | -40.97%61.07M | -15.51%40.38M |
| Financial expense | -61.03%-1.69M | -120.91%-1.57M | -43.92%-490.56K | -220.60%-250.07K | -132.38%-1.05M | -130.21%-712.3K | -47.67%-340.87K | 33.63%-78K | 96.01%-451.3K | 96.35%-309.42K |
| -Interest Income (Financial expense) | -54.54%-1.71M | -108.95%-1.58M | -30.26%-499.36K | -192.01%-253.21K | -127.25%-1.1M | -125.98%-758.35K | -53.34%-383.35K | 32.75%-86.71K | 95.80%-485.66K | 96.15%-335.58K |
| Research and development | -40.55%46.22M | -25.92%40.22M | -41.42%24.83M | -65.80%9.17M | -22.76%77.73M | -31.76%54.29M | -14.14%42.38M | 59.10%26.8M | -3.09%100.63M | -1.14%79.56M |
| Credit Impairment Loss | -10.67%1.47M | 378.17%601.24K | 147.80%468.74K | -109.88%-644.12K | 550.35%1.65M | -138.22%-216.15K | -1,807.96%-980.69K | 1,605.94%6.52M | -76.01%253.23K | -102.09%-90.73K |
| Asset Impairment Loss | ---2.8M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Other net revenue | -166.57%-108.38M | -171.49%-140.02M | -152.36%-138.92M | -201,417.47%-230.64M | -29.40%162.81M | -19.98%195.87M | 12.59%265.34M | -99.88%114.57K | -30.79%230.63M | 284.04%244.77M |
| Fair value change income | -156.36%-56.51M | -169.70%-86.94M | -153.93%-90.11M | -1,970.60%-148.13M | -20.05%100.27M | -11.96%124.73M | 17.04%167.09M | -110.16%-7.15M | -32.45%125.41M | 465.12%141.68M |
| Invest income | -186.31%-51.62M | -177.10%-54.86M | -150.88%-50.45M | -12,408.75%-82.97M | -31.03%59.81M | -21.41%71.15M | 23.45%99.15M | -96.73%674.1K | -34.70%86.71M | 208.29%90.53M |
| -Including: Investment income associates | -239.67%-65.53M | -215.61%-70.92M | -172.24%-65.85M | -2,382.06%-90.93M | -13.35%46.92M | -9.84%61.35M | 30.04%91.16M | -120.91%-3.66M | -40.97%54.15M | 14,620.73%68.04M |
| Asset deal income | ---- | ---- | ---- | ---- | -99.96%2.54K | ---- | ---- | ---- | 1.23%6.65M | 52.26%6.65M |
| Other revenue | -1.46%1.08M | 484.90%1.17M | 1,368.34%1.17M | 1,373.24%1.11M | -90.60%1.09M | -96.66%200.84K | -98.68%79.38K | -98.74%75.24K | 62.30%11.61M | 910.91%6.01M |
| Operating profit | -168.16%-82.97M | -156.13%-121.27M | -146.54%-129.16M | -9,424.25%-225.04M | -52.19%121.74M | -23.67%216.06M | 7.50%277.51M | -98.00%2.41M | -42.00%254.64M | 79.20%283.07M |
| Add:Non operating Income | -21.21%370.32K | 965.63%330.63K | 358.86%130.22K | ---- | 721.75%470.02K | -43.97%31.03K | 15.06%28.38K | 250.48%24.76K | -51.15%57.2K | -50.65%55.37K |
| Less:Non operating expense | 2,129.47%962.44K | 3,016.88%566.77K | 52,876.07%526.77K | 1,065.87%1.1K | -44.43%43.17K | -76.59%18.18K | -60.95%994.35 | -96.29%94.35 | -15.61%77.68K | -34.81%77.68K |
| Total profit | -168.41%-83.57M | -156.23%-121.5M | -146.68%-129.56M | -9,329.95%-225.04M | -52.02%122.16M | -23.66%216.07M | 7.50%277.54M | -97.98%2.44M | -42.00%254.62M | 79.19%283.05M |
| Less:Income tax cost | -125.98%-6.69M | -184.68%-19.3M | -176.06%-21.29M | -1,709.22%-32.69M | -50.44%25.76M | -30.66%22.79M | 9.49%27.99M | -86.58%2.03M | 18.40%51.97M | 31.45%32.86M |
| Net profit | -179.74%-76.87M | -152.88%-102.21M | -143.38%-108.26M | -47,421.38%-192.35M | -52.43%96.41M | -22.74%193.29M | 7.28%249.54M | -99.62%406.47K | -48.71%202.65M | 88.17%250.18M |
| Net profit from continuing operation | -179.74%-76.87M | -152.88%-102.21M | -143.38%-108.26M | -47,421.38%-192.35M | -52.43%96.41M | -22.74%193.29M | 7.28%249.54M | -99.62%406.47K | -48.71%202.65M | 88.17%250.18M |
| Less:Minority Profit | -23.21%-8.02M | -23.70%-4.01M | -46.93%-3.11M | -314.00%-1.73M | -212.23%-6.51M | -32.65%-3.24M | -34.93%-2.12M | 42.73%-417.47K | 70.78%-2.09M | 48.66%-2.44M |
| Net profit of parent company owners | -166.90%-68.85M | -149.97%-98.2M | -141.78%-105.15M | -23,235.01%-190.62M | -49.73%102.92M | -22.21%196.53M | 7.47%251.66M | -99.23%823.94K | -49.11%204.73M | 83.44%252.62M |
| Earning per share | ||||||||||
| Basic earning per share | -166.67%-0.14 | -148.78%-0.2 | -142.31%-0.22 | -23,376.47%-0.3957 | -51.16%0.21 | -21.15%0.41 | 6.12%0.52 | -99.23%0.0017 | -48.81%0.43 | 79.31%0.52 |
| Diluted earning per share | -166.67%-0.14 | -148.78%-0.2 | -142.31%-0.22 | -23,376.47%-0.3957 | -51.16%0.21 | -21.15%0.41 | 6.12%0.52 | -99.23%0.0017 | -48.81%0.43 | 79.31%0.52 |
| Other composite income | -9.12%537.72K | -135.49%-382.43K | -83.08%221.22K | 113.28%61.7K | -79.89%591.67K | -70.21%1.08M | -22.01%1.31M | -238.16%-464.52K | 494.73%2.94M | 1,932.33%3.62M |
| Other composite income of parent company owners | -9.12%537.72K | -135.49%-382.43K | -83.08%221.22K | 113.28%61.7K | -79.89%591.67K | -70.21%1.08M | -22.01%1.31M | -238.16%-464.52K | 494.73%2.94M | 1,932.33%3.62M |
| Total composite income | -178.70%-76.34M | -152.78%-102.59M | -143.07%-108.04M | -331,112.04%-192.28M | -52.82%97M | -23.42%194.36M | 7.07%250.85M | -100.05%-58.05K | -47.87%205.59M | 91.17%253.8M |
| Total composite income of parent company owners | -166.00%-68.32M | -149.89%-98.58M | -141.48%-104.93M | -53,118.56%-190.56M | -50.16%103.51M | -22.88%197.6M | 7.26%252.97M | -99.66%359.41K | -48.28%207.68M | 86.33%256.24M |
| Total composite income of minority owners | -23.21%-8.02M | -23.70%-4.01M | -46.93%-3.11M | -314.00%-1.73M | -212.23%-6.51M | -32.65%-3.24M | -34.93%-2.12M | 42.73%-417.47K | 70.78%-2.09M | 48.66%-2.44M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- | -- | -- | Grant Thornton Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.